A new class of drugs may help in the treatment of acute myeloid leukaemia (AML), according to a joint UK-US project.
Researchers at Ludwig Institute for Cancer Research in Oxford, UK, have pinpointed GSK3 inhibitors as a potential combination therapy with inhibitors of LSD1 – an ‘epigenetic’ enzyme discovered in 2004, which is known to be produced at high levels in AML cells.
The laboratory study suggests the combination might remove the ‘differentiation block’ present in AML, which stops the leukaemic myeloid progenitors from maturing and ensures the leukaemia stem cells keep renewing themselves.
Targeting this differentiation block has been a successful approach in acute promyelocytic leukaemia, which can be cured in 95% of cases with...
16 hours ago
